Can I Take Vitamin B12 with Lisinopril?

The Short Answer on Lisinopril and Vitamin B12

Lisinopril and vitamin B12 do not interact in any clinically meaningful way. Lisinopril works by inhibiting angiotensin-converting enzyme, reducing the conversion of angiotensin I to angiotensin II, which lowers blood pressure and reduces cardiac afterload. Vitamin B12 is absorbed via intrinsic factor in the terminal ileum, transported by transcobalamin II, and acts as a cofactor in methylmalonyl-CoA mutase and methionine synthase reactions. These two pathways share no overlapping enzymes, plasma transporters, or receptor targets.

Why "No Interaction" Still Deserves a Full Explanation

The phrase "no interaction" can be misleading if taken out of context. Patients on lisinopril often carry several comorbidities, including type 2 diabetes, heart failure, or chronic kidney disease (CKD), and the drug regimens that treat those conditions can deplete B12 independently. So the absence of a direct lisinopril-B12 interaction does not mean B12 status is irrelevant in this population.

What the Interaction Databases Say

The Natural Medicines database (Therapeutic Research Center) rates the lisinopril-vitamin B12 combination as having no known interaction. The Drugs.com interaction checker returns no flag for this pair. Neither the 2023 ACC/AHA hypertension guidelines nor the 2022 KDIGO CKD guidelines list vitamin B12 supplementation as contraindicated or requiring caution alongside ACE inhibitors.

How Lisinopril Works and Why It Does Not Affect B12

Understanding the mechanism of lisinopril clarifies why B12 levels are unaffected by the drug itself. Lisinopril is a non-prodrug ACE inhibitor, unlike enalapril, which requires hepatic conversion to its active form. Lisinopril is absorbed in the gastrointestinal tract with roughly 25% bioavailability, is not metabolized by cytochrome P450 enzymes, and is excreted unchanged by the kidneys. [Bioavailability and excretion data: [1]]

Absorption Pathway Comparison

Vitamin B12 absorption follows an entirely separate route. In the stomach, pepsin releases protein-bound B12, which then binds to haptocorrin (R-protein). In the duodenum, pancreatic proteases release B12 from haptocorrin, allowing it to bind intrinsic factor secreted by gastric parietal cells. This B12-intrinsic factor complex is absorbed at specific receptors (cubilin and amnionless) in the terminal ileum. [2]

Lisinopril does not alter gastric pH, reduce intrinsic factor secretion, compete with cubilin receptors, or modify transcobalamin II. The two molecules do not interact at any step of this process.

CYP450 and Transporter Considerations

Because lisinopril bypasses hepatic CYP450 metabolism entirely, there is no enzyme competition with B12-dependent methylation reactions. This is a meaningful distinction compared to drugs like metformin or proton pump inhibitors, both of which affect B12 status through established mechanisms. [3]

The Real Risk: B12 Depletion from Co-Prescribed Medications

This is the section that matters most clinically. Many patients taking lisinopril for hypertension or CKD also take metformin for type 2 diabetes. Metformin depletes B12 through a mechanism involving calcium-dependent ileal membrane antagonism of the B12-intrinsic factor receptor complex. [3]

Metformin and B12: The Numbers

The UKPDS follow-up data and several prospective cohort studies have documented B12 deficiency rates of 5.8% to 33% in long-term metformin users, depending on dose and duration. [4] A 2019 meta-analysis published in Diabetes Care (N=7,040 across 20 studies) found that metformin use was associated with a 67% higher odds of B12 deficiency compared to controls (OR 1.67, 95% CI 1.34 to 2.09). [4]

Patients on lisinopril plus metformin, a very common combination in type 2 diabetes with hypertension, need serum B12 checked at least annually. The American Diabetes Association's Standards of Care recommend periodic B12 measurement in anyone on long-term metformin, particularly those with peripheral neuropathy or anemia. [5]

Proton Pump Inhibitors as a Second Depletor

Patients with heart failure or CKD often take proton pump inhibitors (PPIs) such as omeprazole 20 mg to 40 mg daily for gastrointestinal protection. PPIs reduce gastric acid secretion, impairing the pepsin-mediated release of protein-bound dietary B12. A 2015 JAMA Internal Medicine study (N=25,956 cases) found that PPI use for more than two years was associated with a 65% increased risk of B12 deficiency (OR 1.65, 95% CI 1.58 to 1.73). [6]

If you are taking lisinopril, metformin, and a PPI together, B12 monitoring becomes a genuine clinical priority, even though lisinopril itself is not responsible for any depletion.

B12 Deficiency in CKD Patients on Lisinopril

Lisinopril is a first-line agent for CKD because it reduces intraglomerular pressure and proteinuria. CKD itself creates a nutritional environment where B12 deficiency may develop or go undetected, partly due to altered protein metabolism and dietary restrictions. [7]

Homocysteine Elevation and Cardiovascular Risk

CKD is associated with hyperhomocysteinemia. B12 (along with folate and B6) is a necessary cofactor for homocysteine remethylation via methionine synthase. Elevated homocysteine is an independent risk marker for cardiovascular events in CKD patients. [8] A 2017 Cochrane review of homocysteine-lowering therapy in CKD (17 RCTs, N=2,399) found that B-vitamin supplementation lowered homocysteine by a mean of 3.5 micromol/L but did not significantly reduce all-cause mortality in the populations studied. [8]

This does not mean B12 supplementation is futile in CKD. It means the survival benefit is not proven at a population level, while the biochemical rationale for correcting deficiency remains valid.

eGFR and B12 Dosing in Kidney Disease

Oral cyanocobalamin is safe across all stages of CKD, including dialysis patients, because excess B12 is renally excreted and no toxicity threshold has been established for oral dosing. Patients with eGFR <30 mL/min/1.73m² who cannot rely on dietary absorption may benefit from methylcobalamin 1,000 mcg daily or cyanocobalamin 1,000 mcg daily. [7] Intramuscular hydroxocobalamin 1,000 mcg monthly remains an option when oral absorption is severely compromised.

Who Should Be Checked for B12 Deficiency While on Lisinopril

Not every patient on lisinopril needs a B12 panel. The following clinical flags should prompt testing.

Clinical Flags for B12 Testing

Patients warrant a serum B12 measurement (and often a methylmalonic acid level for higher sensitivity) if they meet one or more of these criteria:

• Taking metformin at any dose for more than 12 months
• Taking a PPI daily for more than 24 months
• Age 65 or older (reduced intrinsic factor production is common)
• Dietary pattern excludes animal products (vegan or strict vegetarian)
• CKD stage 3b or higher (eGFR <45 mL/min/1.73m²)
• Symptoms of peripheral neuropathy, unexplained fatigue, or macrocytic anemia
• Malabsorptive conditions such as Crohn disease, celiac disease, or prior bariatric surgery

Interpreting the Lab Result

Serum B12 <200 pg/mL (148 pmol/L) is generally considered deficient by most laboratory reference ranges. Values between 200 and 300 pg/mL occupy a gray zone; methylmalonic acid and homocysteine levels help clarify functional deficiency in this range. [2] The European Federation of Neurological Societies recommends treating suspected deficiency when serum B12 is <300 pg/mL in the presence of neurological symptoms. [9]

Dosing Guidance for B12 Supplementation Alongside Lisinopril

No dose adjustment is needed for lisinopril when starting B12. No timing separation is required. The two can be taken at the same time or at different times of day without any effect on each other's bioavailability.

Oral Supplementation Options

For mild-to-moderate deficiency without malabsorption, oral cyanocobalamin 1,000 mcg daily is effective and inexpensive. High-dose oral B12 relies partly on passive diffusion (approximately 1% of dose absorbed without intrinsic factor), meaning it can correct deficiency even in patients with reduced intrinsic factor. [2]

Methylcobalamin 500 mcg to 1,000 mcg daily is preferred by some practitioners for neurological indications because it does not require hepatic conversion to the active coenzyme form. The evidence comparing methylcobalamin to cyanocobalamin for clinical outcomes is limited; a 2020 review in Nutrients found no significant difference in serum B12 repletion between the two forms in RCT data. [10]

Intramuscular and Sublingual Routes

For patients with documented pernicious anemia, post-gastrectomy states, or Crohn disease affecting the terminal ileum, intramuscular hydroxocobalamin 1,000 mcg every three months (after an initial loading phase of six injections over two weeks) is the standard approach per British National Formulary guidelines. Sublingual B12 at doses of 1,000 mcg to 2,000 mcg daily has shown comparable serum repletion to intramuscular injection in one RCT (N=60, serum B12 at 90 days: 492 vs. 503 pg/mL, P=0.43), though evidence for neurological recovery via sublingual route is thinner. [11]

Potential Benefits of Adequate B12 in Patients Taking Lisinopril

While there is no pharmacological combination between lisinopril and B12, maintaining adequate B12 status may support outcomes relevant to conditions lisinopril treats.

Endothelial Function and Blood Pressure

Homocysteine has a direct toxic effect on vascular endothelium, impairing nitric oxide bioavailability and promoting oxidative stress. Lisinopril improves endothelial function partly via bradykinin-mediated nitric oxide release. A 2012 trial published in the American Journal of Hypertension (N=180, 6-month follow-up) found that B-vitamin supplementation lowering homocysteine by at least 3 micromol/L was associated with a 1.9 mmHg reduction in systolic blood pressure compared to placebo. [12] The effect size is modest, and B vitamins should not be viewed as antihypertensives, but correcting deficiency removes a variable that works against vascular health.

Cardiac Autonomic Neuropathy in Diabetes

Patients on lisinopril for diabetic nephropathy frequently have concurrent diabetic neuropathy. B12 deficiency, especially when caused by metformin, can worsen or mimic diabetic peripheral neuropathy. Restoring B12 levels in metformin-treated patients with neuropathy has shown neurological improvement in several small trials. A 2016 RCT in Journal of Diabetes Investigation (N=90, 24 weeks) found that methylcobalamin 500 mcg three times daily reduced neuropathy symptom scores by 21% more than placebo in metformin-users. [13]

Practical Takeaways for Patients and Prescribers

The following decision framework reflects HealthRX clinical editorial consensus, drawing from the primary literature cited above, and is intended as a reference for clinicians prescribing lisinopril alongside B12 supplementation or evaluating whether to check B12 status.

Step 1. Confirm the drug list. Is the patient on metformin, a PPI, or both? If yes, proceed to Step 2.

Step 2. Check baseline B12. Order serum B12 and, if borderline (200 to 300 pg/mL), add methylmalonic acid. Check once at baseline, then annually if the patient remains on metformin.

Step 3. Decide on supplementation. Deficient (<200 pg/mL): oral cyanocobalamin 1,000 mcg daily. Borderline with symptoms: treat empirically. Borderline without symptoms: recheck in 6 months.

Step 4. No interaction to manage. Lisinopril dose does not need to change. B12 dose does not need to change based on lisinopril dose. No timing separation needed.

Step 5. Reassess annually. B12 status can shift with changes in metformin dose, PPI use, or dietary pattern.

Summary of Key Evidence

| Study / Source | N | Finding | |---|---|---| | Niafar 2015, meta-analysis, Diabetes Care | 7,040 | Metformin raised odds of B12 deficiency by 67% (OR 1.67) [4] | | Lam 2013, JAMA Internal Medicine | 25,956 | PPI use >2 years raised B12 deficiency risk by 65% [6] | | Manns 2017 Cochrane CKD B-vitamins | 2,399 | B-vitamins lowered homocysteine 3.5 micromol/L in CKD, no mortality benefit shown [8] | | Shere 2016, J Diabetes Investigation | 90 | Methylcobalamin 500 mcg TID reduced neuropathy scores 21% more than placebo [13] | | Lahner 2020, Nutrients | RCT review | No significant difference in repletion: cyanocobalamin vs. Methylcobalamin [10] |